Clinical and Translational Research Core

临床和转化研究核心

• 批准号: 10686318
• 负责人: DEBORAH A HOGAN
• 金额: $ 28.76万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686318
• 关键词: Archives; Area; Basic Science; Biological Assay; Biopsy; Caring; Cells; Clinical; Clinical Research; Collaborations; Collection; Communities; Complement; Consent; Cross-Sectional Studies; Cystic Fibrosis; DNA; Data; Development; Discipline; Disease; Enrollment; Feces; Funding; Gastrointestinal tract structure; Goals; Health; Health Status; Heterogeneity; Home; Immune; Informed Consent; Inpatients; Institution; Institutional Review Boards; Intestines; Investigator-Initiated Research; Laboratories; Longitudinal Studies; Lung; Measures; Metabolic; Methods; Mission; Modeling; National Institute of Diabetes and Digestive and Kidney Diseases; Office Visits; Organ; Outcome; Patients; Physicians; Pilot Projects; Population; Preparation; Process; Prospective Studies; Proteins; Protocols documentation; Pulmonary Cystic Fibrosis; Quality Control; RNA; RNA analysis; Recording of previous events; Records; Rectum; Research; Research Design; Research Personnel; Research Project Grants; Research Support; Resources; Sampling; Sampling Studies; Schedule; Scientist; Serum; Site; Specimen; Surveys; System; Testing; Time; Translational Research; Urine; Visit; Whole Blood; Work; aspirate; biobank; body system; clinical care; clinical center; cystic fibrosis patients; design; dietary; gastrointestinal; gut microbiota; human subject; implementation facilitation; improved; inflammatory marker; insight; member; method development; novel therapeutics; patient population; rectal; research study; sample collection; stool sample; success; treatment effect; treatment response

The mission of the P30-supported DartCF Clinical and Translational Research Core (CTRC) is to increase translational research in studies on the effects of cystic fibrosis disease and treatments on the gastrointestinal tract and organ systems other than the lung. The CTRC supports basic science investigators and physician-scientists by facilitating access to and analysis of clinical specimens from patients with cystic fibrosis and comparator populations. The CTRC provides assistance with all aspects of research with human subjects including study design and approval, implementation, and analysis. In addition, by acting as a central clearinghouse, the CTRC works to coordinate our portfolio of clinically based studies to minimize the burden on our patient population and clinical care team and maximize scientific impact. Samples collected include stool, serum, urine, purified immune cells, bacterial and fungal clinical isolates from patient samples and accompanying patient data as allowed by IRB-approved protocols. The CTRC is able to collect patient samples as part of both longitudinal and cross-sectional studies; longitudinal studies in which samples are paired with patient health measures are particularly important for the analysis of the effects of the gastrointestinal microbiota on outcomes. The CTRC has developed a collection of banked samples for rapid hypothesis testing and this resource can be particularly useful for obtaining preliminary data for new studies. The CTRC is available to all CF researchers at Dartmouth and partner institutions. It is central to the success of our Pilot Projects and other ongoing studies directed by members of the Dartmouth CF research community. The CTRC has four specific aims which are: (1) to support the design and approval of CF clinical and translational research studies, (2) to facilitate collection of specimens and data from CF patients and control subjects, (3) to archive clinical samples for current and future research studies, and (4) to process and analyze clinical specimens efficiently. Through these aims, we seek support research that works towards improving our understanding of CF as a systems-wide disease in order to develop the best possible treatments and cures. !

P30支持的DartCF临床和转化研究核心（CTRC）的使命是增加 在囊性纤维化疾病和治疗的影响研究的转化研究， 胃肠道和肺以外的器官系统。CTRC支持基础科学 研究人员和医生-科学家，通过方便访问和分析临床标本， 囊性纤维化患者和对照人群。CTRC在以下方面提供援助： 人类受试者研究，包括研究设计和批准、实施和分析。在 此外，通过充当中央信息交换所，CTRC致力于协调我们的临床基础产品组合 研究，以尽量减少对我们的患者群体和临床护理团队的负担，并最大限度地提高科学 冲击收集的样本包括粪便、血清、尿液、纯化的免疫细胞、细菌和真菌临床 IRB批准方案允许的患者样本分离株和随附患者数据。的 CTRC能够收集患者样本作为纵向和横断面研究的一部分;纵向 将样本与患者健康指标配对的研究对于分析特别重要 胃肠道菌群对结果的影响。CTRC已经开发了一套 用于快速假设检验的库存样本，这种资源对于获得 新研究的初步数据。CTRC可供达特茅斯和合作伙伴的所有CF研究人员使用 机构职能体系这是我们的试点项目和其他正在进行的研究取得成功的关键， 达特茅斯CF研究社区的成员。该中心有四个具体目标，即：（1） 支持CF临床和转化研究的设计和批准，（2）促进收集 CF患者和对照受试者的标本和数据，（3）存档当前和 未来的研究，和（4）有效地处理和分析临床标本。通过这些目标， 我们寻求支持研究，以提高我们对CF作为一个系统范围的理解 疾病，以开发最好的治疗和治愈方法。 !